
    
      Primary Objectives:

      - To assess the complete remission (CR) rate of magrolimab in combination with pembrolizumab
      in adult subjects with relapsed or refractory cHL

      Secondary Objectives:

        -  To assess the safety and tolerability of magrolimab in combination with pembrolizumab in
           adult subjects with relapsed or refractory cHL

        -  To assess the overall response rate (ORR)
    
  